Drug Type Diagnostic radiopharmaceuticals, Radionuclide Drug Conjugates (RDC) |
Synonyms 68 Ga FAPI 46, [68Ga]Ga-FAPI-46 + [1] |
Target |
Mechanism FAP antagonists(Fibroblast activation protein alpha antagonists), PET imaging(Positron-emission tomography enhancers) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Inactive Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
RegulationOrphan Drug (US) |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Ovarian Cancer | Phase 2 | DK | 07 Jun 2024 | |
Colitis, Ulcerative | Phase 2 | NL | 31 Aug 2023 | |
Crohn Disease | Phase 2 | NL | 31 Aug 2023 | |
Fibrosis | Phase 2 | NL | 31 Aug 2023 | |
Gastrooesophageal junction cancer | Phase 2 | - | 12 Jun 2023 | |
Adenomatous Polyposis Coli | Phase 2 | US | 02 May 2022 | |
Pancreatic Ductal Adenocarcinoma | Phase 2 | US | 02 May 2022 | |
Bile Duct Neoplasms | Phase 1 | US | 27 Aug 2020 | |
Pleural Neoplasms | Phase 1 | US | 27 Aug 2020 | |
Testicular Neoplasms | Phase 1 | US | 27 Aug 2020 |
Not Applicable | - | - | ydckkmveqm(zruifxrrln) = hysymclffy anuweiqpno (kvxjrvkkzx ) | - | 28 Aug 2023 | ||
Not Applicable | - | - | (18F-FDG-PET) | puiutlemsw(leutdqizen) = the average 68Ga-FAPI-46/18-FDG average ratio was higher in LC than in benign lesions (3.64 +/- 1.59 versus 1.89 +/- 0.32) cppvdswkex (zibdpqpjoc ) View more | - | 28 Aug 2023 | |
Not Applicable | - | - | vbuqqxnbkx(hkwmeasxgw) = ivtmbfngvt pdjxwsgkzt (nsrarbnjol ) View more | - | 28 Aug 2023 | ||
Phase 2 | Adenomatous Polyposis Coli FAP expression | 91 | (18F-FDG PET/CT) | johgxklbrx(otvcxclyzz) = gnjeuzpfwk qiooegvfmt (qkeltjqzkq ) | Positive | 28 Aug 2023 |